




E-News | May 6, 2022 | Vol 12, No 4

Creating Surgical Standards to Improve Quality of Surgical Care

Alliance Cancer Care Standards Development Committee



Christina L. Roland, MD, MS, FACS
Chair, Alliance Cancer Care Standards Development Committee



Kelly K. Hunt, MD, FACS
Director, Alliance/American College of Surgeons Clinical Research Program

"A standard is a repeatable, harmonized, agreed upon and documented way of doing something. Generally speaking, standards contain technical specifications or other precise criteria designed to be used consistently as a rule, guideline, or definition. Standards result from collective work by experts in a field and provide a consensus at the time when the standards are developed." [Read more.](#)

Alliance DSMB:

Who Are We and What Do We Do?

Alliance Data and Safety Monitoring Board



Jeffrey J. Kirshner, MD, FACP, FASCO
Chair, Alliance Data and Safety Monitoring Board

"In order to ensure patient safety, all randomized phase II and phase III (and other selected phase II) trials sponsored by the National Cancer Institute (NCI) require monitoring by a Data and Safety Monitoring Board (DSMB)." [Read more.](#)

**MAY IS NATIONAL
BLADDER CANCER
AWARENESS MONTH**



Learn more about Alliance Bladder Cancer Trials

- **A031701: Muscle-invasive Bladder Cancer**
- **A031803: CG-unresponsive Non-muscle Invasive Bladder Cancer**
- **A031901: Metastatic Urothelial Carcinoma**
- **A032001: MAIN-CAV: Metastatic Urothelial Carcinoma**
- **A032002 ART: Platinum Ineligible/Refractory Metastatic Urothelial Cancer**

Spotlight on Alliance Trials

- **A071702 (Somatically Hypermutated Recurrent Glioblastoma)**
 - **A171901 (Lung Cancer in Older Adults)**

2022 Alliance Spring Hybrid Group Meeting Convenes May 11-14



Remembering Jeff A. Sloan, PhD
Professor of Biostatistics and Oncology
Mayo Clinic

Alliance in the News / Cancer Research Briefs

[Geriatric Assessment for Older Adults Receiving Less Intensive Therapy for Acute Myeloid Leukemia: Report of CALGB 361101](#)

[Sanofi Provides Update on Phase 2 Study Evaluating Amcenestrant in ER+/HER2- Advanced or Metastatic Breast Cancer](#)

[KDR Genetic Predictor of Toxicities Induced by Sorafenib and Regorafenib](#)

[A Wave of New Cancer Treatments Challenges Community Oncologists to Keep Up](#)



Alliance for Clinical Trials in Oncology Office of the Group Chair
221 Longwood Avenue, Room 108, Boston, MA 02115